SARS-COV2 pandemic has caused profound challenges in health care systems worldwide. Patients affected by hematological neoplasms appear to be particularly at risk of developing COVID-19 complications, with unfavorable outcomes. Here, we present the case of a 57-years-old woman diagnosed with severe COVID-19 pneumonia and concurrent acute myeloid leukemia (AML). At the time of diagnosis, it was decided to postpone leukemia therapy to enable adequate COVID-19 pneumonia treatment. When her conditions related to pneumonia improved, the combination of Azacitidine-Venetoclax was used as first-line treatment instead of conventional intensive chemotherapy. At the end of the first two cycles, the patient showed complete remission, and a post-remission consolidation with allogeneic hematopoietic stem cell transplantation has been planned. This case suggests that Azacytidine-Venetoclax induction may represent a valid and safe alternative to intensive chemotherapy in the challenging setting of patients with a concomitant diagnosis of AML and severe COVID-19 infection.

中文翻译：

---

急性髓系白血病和症状性 COVID-19 感染的并发诊断：阿扎胞苷-维奈托克联合治疗成功的病例报告。

SARS-COV2 大流行给全球卫生保健系统带来了深刻挑战。受血液系统肿瘤影响的患者似乎特别有可能发生 COVID-19 并发症，结果不利。在这里，我们介绍了一名 57 岁女性，被诊断患有严重的 COVID-19 肺炎并并发急性髓系白血病 (AML)。在诊断时，决定推迟白血病治疗，以实现对 COVID-19 肺炎的充分治疗。当她与肺炎相关的病情好转时，阿扎胞苷-维奈托克的组合被用作一线治疗，而不是传统的强化化疗。在前两个周期结束时，患者表现出完全缓解，并计划进行同种异体造血干细胞移植的缓解后巩固治疗。